| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Research Abstract |
Our cancer vaccination therapy using these peptides was welltolerated for oral cancer . 5 patients showed a postoperative local recurrence and metastasis(peritoneal dissemination;1 case, lung metastasis;1 case , cervical lymph node metastasis; 2cases and local recurrence; 1case). However , metastatic foci without peritoneal disseminationwere removed and all cases are continued vaccination therapy using these peptides. In all ofcases, recurrence and/or metastasis are not recognized after treatment.In the HLA-24(+) group, ELISPOT assay indicated that the URLC10-, CDCA1-, andKOC1-specific CTL responses were observed after the vaccination in 88.2%, 82.4%, and 52.9%,of the HLA-24(+) group, respectively. The patients showing URLC10 and CDCA1 specificCTL responses revealed the better clinical response, respectively. Conclusions: V accination using these peptides was well tolerated, and measurable immuneresponses and antitumor efficacy are observed. The immune response induced by thisvaccination can make their prognosis better for head and neck cancer patients
|
